Healthcare resource utilization and costs among patients with psoriasis treated with ixekizumab or adalimumab over 2 years of follow-up in real-world settings
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Medical Economics"
DOI: 10.1080/13696998.2022.2081417
Abstract: Abstract Aims To compare long-term healthcare resource utilization (HCRU) and costs among patients who initiated ixekizumab (IXE) or adalimumab (ADA) for treatment of psoriasis in the United States. Methods Adult patients with psoriasis who had… read more here.
Keywords: ada users; ixe ada; healthcare resource; resource utilization ... See more keywords